Dana-Farber Cancer Institute | Strategic Alliance Partners

April 02, 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

March 18, 2025

Elizabeth Lee, MD, discusses the efficacy of rinatabart sesutecan in patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

March 17, 2025

The median DOR with Rina-S was not reached and the treatment was well tolerated in patients with FRα-unselected platinum-resistant ovarian cancer.

March 17, 2025

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, is launching a project focused on translocation renal cell carcinoma.

March 13, 2025

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

March 12, 2025

Treatment with casdatifan was well tolerated and showed meaningful clinical activity in patients with previously treated ccRCC.

March 10, 2025

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

March 04, 2025

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

February 28, 2025

Lakshmi Nayak, MD, discusses the mechanism of action of emavusertib and the study of this drug relapsed/refractory primary and secondary CNS lymphoma.

February 28, 2025

Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.

February 21, 2025

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

February 19, 2025

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

February 12, 2025

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

February 12, 2025

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

February 10, 2025

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

February 05, 2025

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

January 29, 2025

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

January 29, 2025

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

January 28, 2025

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.

January 28, 2025

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.